Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06671132 · ClinicalTrials.gov registry record · Phase 2
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)
A Phase 2 study of Chronic Pain and Low Back Pain, sponsored by Evon Medics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 2
- Study locations
NCT06671132: Recruiting Phase 2 study of Chronic Pain and Low Back Pain, sponsored by Evon Medics.
NCT06671132 is a Phase 2 study of Chronic Pain and Low Back Pain that is actively recruiting participants, run by Evon Medics. The registered enrollment target is 220 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06671132, a Phase 2 study of Chronic Pain and Low Back Pain, is actively recruiting participants, sponsored by Evon Medics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overarching goal of this study phase, Phase II component is to perform a randomized clinical trial of the refined Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain \[CBOT-Pain (or CBOT-P)\] from Phase I, compared to sham Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) in Chronic Low Back Pain (CLBP) to determine its short- and long-term effectiveness on Pain, Negative Affect (NA), Cognition and Cortical Brain Structure (PACS), long-term safety, and indications. The investigators will perform a randomized clinical trial of the refined CBOT-P from Phase I, compared to sham CBOT in CLBP. Aim 2.1: To determine if CBOT-P significantly influences: (1) acute and long-term reduction of pain severity, and (2) acute and long-term reduction of negative affect. The hypothesis is that optimized CBOT will produce faster, stronger, and longer-lasting improvements in pain severity, NA severity, cognitive impairments, and sleep and functional outcomes. Aim 2.2 To determine if CBOT-P significantly prevents or reduces progressive shrinkage in the orbitofrontal cortex (OFC), cingulate cortex, and hippocampus. MRI will be acquired at baseline and 6th month. An integrative analysis will be conducted to determine the link between changes in brain structure and cognitive trajectory. The hypothesis is that the CBOT optimized with BCP significantly attenuates shrinkage in OFC and other prefrontal cortex (PFC) regions, compared to the Sham intervention.
Primary Outcome
Change in 11-point score PROMIS Numeric Rating Scale v1.0 - Pain Intensity from baseline. The Numeric Rating Scale measures each consist of a single item rating pain on average over the past 7 days from 0 (no pain) to 10 (worst pain).
Conditions Studied
Interventions
- COMBINATION_PRODUCT Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain
- COMBINATION_PRODUCT Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)
Study Locations (2)
District of Columbia
- Howard University - Washington D.C.
Maryland
- Global Pain Management LLC - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2024-10-23 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 2 |
What NCT06671132 shows while recruiting
NCT06671132 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain is the first listed.
NCT06671132 reports a single indexed study location in District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT06671132 about?
NCT06671132 is a clinical study titled "Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)". The overarching goal of this study phase, Phase II component is to perform a randomized clinical trial of the refined Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain \[CBOT-Pain (or CBOT-P)\] from Phase I, compared to sham Computerized Chemosensory-Based Orbitof...
What is the current status of trial NCT06671132?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2024-10-23. Estimated completion is 2026-01-30.
What conditions does trial NCT06671132 study?
This clinical trial studies the following conditions: Chronic Pain, Low Back Pain.
What interventions are being tested in trial NCT06671132?
The interventions under investigation include: Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain (COMBINATION_PRODUCT), Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06671132?
This trial is sponsored by Evon Medics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06671132 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06671132's enrollment target sits among peer trials
220 76th of 301 higher than 225 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
RECRUITING · Phase 2
-
The Role of Brain Dopamine in Chronic Pain
RECRUITING · Phase 2
-
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Dronabinol as an Adjunct for Reducing Pain
RECRUITING · Phase 2
-
Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI